MaxCyte
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Maryland, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
9713 Key West Ave, Rockville, Maryland, ...Phone Number
(301) 944-1700Website
www.maxcyte.comRevenue
$32.3 MillionStock Symbol
MXCTIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
2
1
1
About MaxCyte
MaxCyte is a clinical-stage global cell-based therapies and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs.Explore more
MaxCyte Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MaxCyte your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if MaxCyte had a recent Job posting/layoffs
Funding: Get notified immidiatlly once MaxCyte has new funding data
Check if MaxCyte has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at MaxCyte
Product Launch: Get notified when MaxCyte launches new products
MaxCyte, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on MaxCyte recently announced quarterly report
Check out if MaxCyte is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to MaxCyte
Compare insights from companies similar to MaxCyte, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
MaxCyte is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
MaxCyte is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about MaxCyte.
MaxCyte financials insights
Gather financial insights about MaxCyte, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2003
Series A
$8M
2004
Series B
$10.7M
2016
Stock Offering
$14.4M
2019
Share Placement
$12.3M
2020
Debt
$1M
Share Placement
$30.9M
MaxCyte Tech Stack
A closer look at the technologies used by MaxCyte
Most Recent Scoops
Person-Based
Product Development, Medical Research, Pharmaceuticals
Person-Based
Product Launch, Research & Development, Regulations
Person-Based
Earnings, Finance
Project
continues to advance its SeQure assay services and licenses, expecting year-over-year growth in 2026 as the regulatory environment evolves favorably, with the company anticipating that SeQure assays will become an industry standard for off-target risk assessment in gene editing.
Bioengineering, Medical Research
Earnings
Earnings, Finance
MaxCyte News & Media
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
ROCKVILLE, Md., Aug. 19, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced the launch of the CHANGE-seq-BE™ and ONE-seq-BE™ off-target nomination assays. Available through MaxCyte’s SeQure™ service, these assays address a key gap in genome editing characterization by offering sensitive nominatioMaxCyte Reports Second Quarter 2026 Financial Results
ROCKVILLE, Md., Aug. 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its second quarter ended June 30, 2026 financial results and reiterated its 2026 guidance.MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development
Technology License Partnership provides Genentech access to MaxCyte’s portfolio of platform technologies across research, development, and manufacturing workflows Technology License Partnership provides Genentech access to MaxCyte’s portfolio of platform technologies across research, development, and manufacturing workflowsMaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development
Technology License Partnership provides Genentech access to MaxCyte’s portfolio of platform technologies across research, development, and manufacturing workflows Technology License Partnership provides Genentech access to MaxCyte’s portfolio of platform technologies across research, development, and manufacturing workflows
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding MaxCyte
Sign Up For FreeTo access detailed company insights
MaxCyte is a clinical-stage global cell-based therapies and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs.... Read More
